Galectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer

Reuters11-10

Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer

Galectin Therapeutics Inc. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582871120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582871120","market":"fut","top_or_hot":-1,"title":"Galectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GALT\">Galectin Therapeutics Inc</a>. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GALT\">Galectin Therapeutics Inc</a>. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9PGg4L:1","article_id":"2582871120","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582871120","pubTimestamp":1762780885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Galectin Therapeutics Inc. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis  cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.Disclaimer: This news brief was created by Pub","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GALT":"Galectin Therapeutics Inc"},"translate_title":"Galectin Therapeutics公布了治疗MASH肝硬化和癌症的galectin-3抑制剂的研发进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GALT":0.9},"content_text":"Galectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer\n    \n\nGalectin Therapeutics Inc. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582871120","isCrawlerRequest":true}